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Abstract
Concurrent radiation and chemotherapy is a standard treatment of patients with
cervical cancer in FIGO stages IB2-IVA. Chemotherapy given in the same time as
irradiation improved survival significant, but not involves all patients. Cancer
recurrence is the most common treatment failure in patients with advanced
tumor. Further improvement in the treatment of advanced cases is essential.
The increasing knowledge about new biologic markers and better ability to predict
risk of cancer recurrence is very important for construction of more effective
treatment strategies. Currently, there is considerable interest of role of cyclo-
oxgenase-2 in cervical neoplasia. A lot of cancers in different localizations appear
to overexpress the cyclooxygenase-2, which may have an important role in
carcinogenesis. Ongoing clinical trials, clinical studies have shown the positive
therapeutic effect of COX-2 inhibitors and may allow to increase understanding
of this novel targeted approach for cervical cancer control.
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Introduction
Irradiation associated with chemotherapy (radiochemotherapy) is
a standard treatment of loco-regional advanced cervix cancer. Despite
overall and disease free survival improvement (on 12 and 18% respectively),
cancer recurrence has been observed in a significant percentage
of patients. Further improvement in the treatment of advanced cervix
cancer is desperately needed. FIGO stage, lymph nodes status, tumor size,
hemoglobin level are well recognized prognostic factors for radio-
chemotherapy results, but in some patients with the radioresistance tumor,
aggressive clinical course treatment results were not always correlated
with the mentioned factors. Recognition of biological tumor markers
allowing for better treatment failure risk prediction is very important in
developing of new therapeutic methods and better patients selection for
different methods of treatment. 
For fifteen years the role of cyclooxygenase-2 (COX-2) in carcinogenesis
and tumor progression has been a subject of a lot of research.
Cyclooxygenase enzyme exist in two main isoenzyme forms (Figure 1).
COX-1 is expressed in most of tissues and catalyzes the synthesis
of prostaglandins from arachidonic acid, which are required for normal,
physiologic functions e.g. gastrointestinal cytoprotection and platelet
activity, it is also expressed in endothelial cells, renal microvasculature
[1, 2]. COX-2 is not detectable in most normal tissues, and basal conditions.
It is induced by cytokines (inflammatory response), growth factors, tumor
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macrophages, epithelial, endothelial cells, fibroblast
and thus contributes to increased prostaglandins
synthesis in inflamed and neoplastic tissues [2, 3].
COX-2 overexpression was observed in early
carcinogenesis stages in colon cancer and
carcinogenesis suppression was observed in mice
disable of COX-2 gen. COX-2 overexpression has
been noticed in different types of cancer including
pancreatic, lung, breast, colorectal, esophageal,
gastric, bladder, ovary, endometrial and cervix
cancer [4-6].
Experimental evidence of a role of COX-2 in
carcinogenesis
COX-2 contribution in carcinogenesis may go
through a different mechanisms, including procarcino-
gens activation like benzopyren found in tobacco and
grilled foods [7], increase of cancer cell invasiveness,
inhibition of apoptosis, immunosupression and
stimulation of angiogenesis (Figure 2). Inhibition
of apoptosis has been observed in rat intestinal cells:
overexpression of COX-2 lead to increase the anti
apoptotic protein Bcl-2 level and to suppression
of apoptosis and allow to survival of cancer cell [8].
The invasive potential of human colon cancer cells
may increased when COX-2 is overexpressed: it is
associated with activation of metalloproteinase-2,
which promote invasion. COX-2 induce prostaglandin
E2, which suppresses humoral and cellular immune
response and stimulates immunosuppressive
cytokines. This effect can be reversed by COX-2
inhibition, as it was observed in a murine Lewis lung
carcinoma model [8-10]. 
In experimental conditions on colon carcinoma
cell line angiogenesis inhibition by the selective
COX-2 inhibitor NS 398 has been proven [11].
COX-2 and irradiation in cell cultures
The mechanism of COX-2 inhibited radio-
sensitivity is not completely understood. Steinauer
et al. demonstrated that COX-2 can be blocked by
the use of a specific inhibitor before radiotherapy
[12]. In experimental cell lines an enhancement
of tumor cell radiosensitivity by selective inhibitor
of COX-2 has been shown in murine sarcoma cell
culture, human cancer cell lines, and in rat intestinal
epithelial cells COX-2 overexpressing [13, 14]. This
increasing radioresponse may be attributable to
enhancement of radiation-induced apoptosis,
accumulation of cells in the radiosensitive G2-M
phase of the cell cycle and inhibition of sublethal
radiation damage repair. The radiation-induced
G2-M arrest by using selective COX-2 inhibitor was
observed also in the COX-2 low expressing cells,
caused by another not very understanding
mechanism. Selective COX-2 inhibitor showed
synergistic with irradiation antitumor activity
without increasing radiation damage to normal
tissue in an sarcoma cell line model. 
COX-2 and cytostatics in cell cultures
Interaction between COX-2 inhibitors and cisplatin
and paclitaxel has been investigated in non-small
cell lung cancer and small cell lung cancer in vitro:
sulindac, the non specific COX-2 inhibitor enhanced
growth inhibition of cytostatics [15]. In the same cell
lines induction of apoptosis has been observed when
a selective COX-2 inhibitor was given with cisplatin,
etoposide, irinotecan, docetaxel. The synergistic
effects between chemotherapy and COX-2 inhibitors
may be considered in the treatment [16].
OX-2 and HPV
The role of human papilloma virus oncoproteins
E6 and E7 in cervix cancer genesis have been well
known. The effects of virus proteins E6 and E7 on
COX-2 expression are unknown. In experimental





Figure 1. Synthesis of prostaglandins and tromboxans from
arachidonic acid
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and prostaglandin E2 were detected in HPV16 E6-
and E7-expressing cervical cancer cells culture
compared with HPV-negative cervical cancer cell
line. HPV16 oncoproteins stimulated EGFR, induced
also some coactivators/corepressor and in this way
induced COX-2 transcription. Munoz et al. [17] and
zur Hausen et al. [18] have shown that HPV may
play role in induction of COX-2. Kim et al. [19]
suggested that COX-2 overexpression was not
correlated with HPV positivity. Molecular changes
caused by HPV may not affect the synthesis
of COX-2 in cervical cancer cells. Similar conclusion
have been made by Song et al. [20].
COX-2, cervical cancer and clinical studies
The increasing knowledge of proteins, which
physiologic levels use to be disturb in time of carcino-
genesis and cancer progression and development
of new immunohistochemical techniques have lead
to use biomarkers as a prognostic and/or predictive
factors. The expression of COX-2 has been detected
in cervical intraepithelial neoplasia (CIN) and in
cervical cancer tissue. Most authors suggested, that
COX-2 is undetectable in normal cervix tissue. A very
sparse suggested, that normal cervical tissue
expressed COX-2 more frequently than cervical
cancer, but their clinical material concerned a very
small groups of patients [21].
A few studies tested correlation between COX-2
expression and pathological parameters in cervix
cancer. The relationship between tumor grade and
COX-2 expression is not very clear. Both low grade
of histological differentiation and high COX-2
expression are accepted as a poor prognostic factors,
but Chen et al. [22] observed inverse relationship:
the expression of COX-2 in grade I tumor was
significantly higher compared to grade II and III. Chen
put hypothesis, that COX-2 expression is important
first of all during carcinogenesis and later its role
might be not very significant. Ferrandina et al. [23],
Lee et al. [24], Dai et al. [25] did not observe
differences with respect to tumor grade and COX-2
expression. These results suggest, that COX-2 is not
involved in tumor grade determination or, that
COX-2 expression might be reduced in the presence
of aggressive cellular differentiation. 
Kim et al. [26], Ryu et al. [27] have shown, that
COX-2 overexpression correlated with stage, risk
of lymph nodes metastasis and parametrial
involvement. Similar results have been shown by
Pyo et al. [28] and Ferrandina et al. [23]: they
attributed this correlation to a direct association
high COX-2 level and advanced tumor stage and
tumor size. Some of them suggest more important
role of COX-2 expression in local tumor spread (also
on context of risk of lororegional recurrence) than
in nodal metastases. Others, could not demonstrate
any correlation between COX-2 expression and
parametrial invasion and/or lymph node metastases
[22, 29]. Dursum et al. [30] observed significantly
higher expression of COX-2 in patient with cervix
tumor size > 4 cm and with lymphovascular space
invasion (LVSI). The same relationship between
COX-2 level and LVSI was observed by Chen et al.
[22] and Lee et al. [24]. Some researches could not
find any dependence between COX-2 expression
and cervix cancer tumor size [22, 31].
Relationship between HPV status and COX-2
expression is analyzed in a few clinical reports. HPV
infection may play an important role in stimulation
of COX-2 as it was shown by Munoz et al. [32] and
zur Hausen et al. [33]. On the other hand Kim et al.
[19] and Kulkarni et al. [6] did not find correlation
between COX-2 expression and HPV positivity. This
lack of relationship may be caused by different
pathways in cervical carcinogenesis, or molecular
changes caused by HPV may not have influence on
COX-2 overexpression.
The analysis of radiotherapy and radiochemo-
therapy results in patients with cervical cancer
indicate that high COX-2 expression may be
correlated with lower survival. Kim et al. [31] noticed
significantly higher incidence of local failure for
patients with high COX-2 expression then for
patients COX-2 negative. Pyo et al. [28], Kang et al.
[34], Ferrandina et al. [35, 36], noticed decreased
survival in patients with elevated COX-2 expression.
Ferrandina et al. [37] in the group of 175 patients
with different stage of cervix cancer confirmed that
COX-2 status in both tumor and stroma com-
partment (ratio) can help in identification of cervix
cancer patients with low probability of response to
neoadjuvant chemotherapy and preoperative
chemoradiotherapy. 
The mechanism by which COX-2 is up-regulated
in cervix cancer is not very clear. Kulkarni et al. [6]
suggest first deregulation of EGFR signaling
pathway and then COX-2 increased expression.
Most of authors concentrated on aftermath
of COX-2 expression. In Stolina et al. [10] study
COX-2 expression is correlated with antagonize host
immunogenity against cancer cells, similarly Chen
et al. [38] suggested that high COX-2 level might be
important in inhibiting host immune system
(indicated by lower tumor intraepithelial CD8+
lymphocyte count) which is poor prognostic factor
for patients. Ryu et al. [39] have shown in group
of cervix cancer patients treated by radical surgery
that expression of COX-2 may downregulate
apoptosis and in this way enhance invasion and
metastases. Nagai et al. [40] find interesting
correlation between lack of COX-2 expression and
significant induction of apoptosis during neo-
adjuvant chemotherapy. In patients with COX-2
overexpression the difference in apoptotic index
before and after chemotherapy is not considerable.
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Initially COX-2 level may be a predictor of response
of chemotherapy. It has been documented by better
pathological response to chemotherapy in patients
with COX-2 protein negative. The same reported
Ferrandina et al. [35]. Ishikawa et al. [41] pro-
spectively assessed apoptotic index in specimens
taken before and during radiotherapy (after
the dose of 9 Gy) and they find significant negative
correlation between initial COX-2 expression and
apoptotic index during treatment. Complete
response rate was 80% for COX-2 negative patients
and 59% for patients with COX-2 overexpression.
The 2-year local control was statistically better for
COX-2 negative patients. Level of COX-2 expression
before radiotherapy may help to predict response
for treatment. Concurrent chemotherapy had no
impact on apoptotic index measured during
radiotherapy probability because of a limited effect
of low dose of cisplatin. 
COX-2 inhibitors, cervical cancer and clinical studies 
A lot of epidemiologic, experimental and clinical
studies suggest that nonsteroidal anti-inflammatory
drugs (NSAIDs) have anticancer activity. This group
of drugs have anti-inflammatory effects due to
inhibition the synthesis of prostaglandins, but
prostaglandins mainly E2 have also the important
role during carcinogenesis, and the inhibition
of prostaglandins formation by blocking COX-2 may
protect against many types of cancers like breast,
colon, head and neck, skin, cervix and ovary cancer. 
Rao et al. [42] showed that indomethacin, non
specific COX inhibitor protects against chemically
induced cervical cancer in mouse. Recently
Ferrandina et al. [43] in pilot study have shown that
treatment with celecoxib, a selective COX-2 inhibitor
patients with cervical cancer could affect important
aspects of tumor biology: prostaglandins E2 level,
microvessel density, apoptosis level. 
Gaffney et al. [44] in phase II study of acute
toxicity for Celebrex and chemoradiation in patients
with locally advanced cervix cancer found a high
incidence of acute reactions. Most frequent
toxicities were hematologic, gastrointestinal, skin.
Herrera et al. [45] in a prospective phase I-II trial
of COX-2 inhibitor Celecoxib in patients with cervix
cancer observed higher than expected late com-
plications mainly rectovaginal fistula. There are some
limitations in these two studies with regard to
the effectiveness of celecoxib in cervical cancer
treatment: pretreatment COX-2 expression was not
examined. The most effectiveness of COX-2 inhibitors
would be expected in COX-2 overexpressing tumors.
The toxicities of NSAIDs include gastrointestinal
bleeding, renal toxicity, inhibition of platelet function.
COX-2 selective inhibitors newer generation
(valdecoxib, parecoxib) are more safety particularly
in gastrointestinal tract. In cancer treatment it is very
important to consider agents that are effective and
have minimal toxicity. Some reports suggest that
COX-2 inhibitors increase risk for stroke, myocardial
infarction up to 3.7 fold compare with placebo, some
authors conclude that risk is dose-related. On
the other hand, on most in vitro studies the COX-2
inhibitors concentration in cancer tissues that was
correlated with optimal results was higher than
35 μmol/l [46, 47]. This suggest higher doses may be
needed for significant antitumor effect. According to
these results, if proper selection of COX-2 inhibitor,
the smallest effective dose giving in as short as
possibly time during radiotherapy could be
recognized, more effective treatment for advanced
cervix cancer may be defined. 
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